SlideShare uma empresa Scribd logo
1 de 60
Asthma Zhiwen Zhu   Pulmonary & Critical Care Medicine  1st Affiliated Hospital of Sun Yat-Sen University
Beethoven Ludwig van He was a patient with asthma, and died in 1827.
Teresa Deng She was also a patient with asthma, and died in 1995.
Asthma incidence of children
G   IN A lobal  itiative for  sthma
Asthma (GINA Workshop)  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Definition of Asthma ,[object Object],[object Object],[object Object]
Epidemiology ,[object Object],[object Object],[object Object],[object Object]
Worldwide Variation in Prevalence of Asthma Symptoms International Study of Asthma and Allergies in Children (ISAAC) Lancet  1998;351:1225
Increasing Prevalence of Asthma in Children/Adolescents 0 5 10 15 20 25 30 35 1992 1982 1989 1975 1992 1982 1994 1989 1992 1982 1992 1982 1991 1979 1989 1966 Finland (Haahtela  et al ) Sweden (Aberg  et al ) Japan (Nakagomi  et  al ) Scotland (Rona  et al ) UK (Omran  et al ) USA (NHIS) New Zealand (Shaw  et al ) Australia (Peat  et al ) { Prevalence (%) { { { { { { {
70 60 50 40 30 20 85 86 87 88 89 90 91 92 93 94 Rate/1,000 Persons Year <18 18-44 45-64 65+ Total (All Ages) Age (years) Trends in Prevalence of Asthma   By Age, U.S., 1985-1996 95 96 80
Risk Factors for Asthma ,[object Object],[object Object]
Risk Factors that Lead to  Asthma Development ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Factors that Exacerbate Asthma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Mechanisms Underlying the Definition of Asthma ,[object Object],[object Object],INFLAMMATION Airway Hyperresponsiveness Airflow Obstruction Risk Factors (for exacerbations) Symptoms
 
Asthma Diagnosis ,[object Object],[object Object],[object Object],[object Object]
Clinical Manifestation of Asthma ,[object Object],[object Object],[object Object],[object Object],[object Object]
Physical Examination ,[object Object],[object Object],[object Object]
Measurement of Lung Function ,[object Object],[object Object],[object Object],[object Object],[object Object]
Measurement of Lung Function ,[object Object],[object Object],[object Object]
Typical Spirometric (FEV 1 ) Tracings 1 Time (sec) 2 3 4 5 FEV 1 Volume Normal Subject Asthmatic (After Bronchodilator) Asthmatic (Before Bronchodilator) Note:  Each FEV 1  curve represents the highest of three repeat measurements
Measurement of Lung Function ,[object Object],[object Object]
Arterial blood gas ,[object Object],[object Object]
Measurement of Allergic Status ,[object Object],[object Object]
Standards of Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Differential Diagnosis ,[object Object],[object Object],[object Object],[object Object]
Definition of COPD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GOLD 2004
Pointers that differentiate  asthma from COPD   COPD Asthma History     Smoker or ex-smoker Nearly all Possibly Symptoms under age 45 Uncommon Often Chronic productive cough Common Uncommon Breathlessness Persistent and progressive Variable Winter bronchitis Common Uncommon Investigations     Serial PEF Obstructive picture May be normal Day to day and diurnal variation Reversibility testing Minimal variation Usually<15% or 200ml change  Usually>15% or 200ml change
Classification of Severity ,[object Object]
Classification of Severity of chronic stable asthma CLASSIFY SEVERITY Clinical Features Before Treatment Symptoms Nocturnal Symptoms FEV 1  or PEF STEP 4 Severe Persistent STEP 3 Moderate Persistent STEP 2 Mild Persistent STEP 1 Intermittent Continuous Limited physical activity Daily Attacks affect activity > 1 time a week  but < 1 time a day < 1 time a week Asymptomatic and normal PEF between attacks Frequent > 1 time a week > 2 times a month  2 times a month  60% predicted Variability > 30% 60 - 80% predicted  Variability  > 30%  80% predicted Variability 20 - 30%  80% predicted Variability < 20% The presence of one feature of severity is sufficient to place  patient in that category.
Classification of Severity
Classification of severity of asthma exacerbation <91 >45 <60 Relative bradycardia Consciousness Impending respiratory failure <91 >45 <60 <60% >120 >30 At rest Severe 91~95 <45 60~80 60-80% 100~120 ↑ With talking Moderate >95 <45 normal >80% <100 ↑ With activity Mild SaO2 PaCO2 PaO2 PEF/FEV1 HR RR breathlessness
Six-Part Asthma Management Program 1. Educate patients to develop a partnership in asthma management 2. Assess and monitor asthma severity with symptom reports and measures of lung function as much as possible 3. Avoid exposure to risk factors 4. Establish medication plans for chronic management in children and adults 5. Establish individual plans for managing exacerbations 6. Provide regular follow-up care
Six-part Asthma Management Program Goals of Long-term Management ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program Control of Asthma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
. Six-Part Asthma Management Program ,[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program Part 1:  Educate Patients to Develop a Partnership   ,[object Object],[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program Part 2:  Assess and Monitor Asthma Severity with Symptom Reports and Measures of Lung Function ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program Part 3:  Avoid Exposure to Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program Part 4: Establish Medication Plans for Long-Term Asthma Management ,[object Object],[object Object],[object Object]
Part 4:  Long-term Asthma Management Stepwise Approach to Asthma Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Part 4:  Long-term Asthma Management Pharmacologic Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Part 4:  Long-term Asthma Management   Pharmacologic Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
© GSK 2002
© GSK 2002
© GSK 2002
Part 4:  Long-term Asthma Management Stepwise Approach to Asthma Therapy - Adults Reliever: Rapid-acting inhaled β 2 -agonist prn ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],STEP 1: Intermittent STEP 2: Mild Persistent STEP 3: Moderate Persistent STEP 4: Severe Persistent STEP Down Outcome: Asthma Control Outcome:  Best   Possible Results Alternative controller and reliever medications  may be considered (see text).  Controller: None -Theophylline- SR -Leukotriene  -Long-acting inhaled β 2 - agonist -Oral corticosteroid
Stepwise Approach to Asthma Therapy: Adults   Step 1:  Intermittent Asthma  None required Rapid-acting   inhaled   2 -agonist for symptoms (but < once a week) Rapid-acting   inhaled   2 -agonist, cromone, or leukotriene modifier  before exercise or exposure to allergen ,[object Object],[object Object],[object Object],[object Object],Daily Controller Medications Reliever  Medications
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Stepwise Approach to Asthma Therapy:  Adults Step 2: Mild Persistent Asthma Daily Controller Medications Reliever Medications
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Stepwise Approach to Asthma Therapy:  Adults Step 3: Moderate Persistent Asthma Daily Controller  Medications Reliever Medications
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Stepwise Approach to Asthma Therapy:  Adults Step 4: Severe Persistent Asthma Daily Controller  Medications Reliever Medications
Part 4:  Long-term Asthma Management Stepwise Approach to Asthma Therapy - Adults Reliever: Rapid-acting inhaled β 2 -agonist prn ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],STEP 1: Intermittent STEP 2: Mild Persistent STEP 3: Moderate Persistent STEP 4: Severe Persistent STEP Down Outcome: Asthma Control Outcome:  Best   Possible Results Alternative controller and reliever medications  may be considered (see text).  Controller: None -Theophylline- SR -Leukotriene  -Long-acting inhaled β 2 - agonist -Oral corticosteroid
Six-part Asthma Management Program Part 5: Establish Plans for Managing Exacerbations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program Part 5: Managing Severe Asthma Exacerbations ,[object Object],[object Object]
Emergency Department Management Acute Asthma Respiratory Failure Admit to ICU Good Response Observe for at least 1 hour If Stable, Discharge to Home Initial Assessment History, Physical Examination, PEF or FEV 1 Initial Therapy Bronchodilators; O 2  if needed Incomplete/Poor Response  Add Systemic Glucocorticosteroids Good Response Discharge  Poor Response Admit to Hospital
Six-part Asthma Management Program Part 6: Provide Regular Follow-up Care ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Six-part Asthma Management Program:   Summary ,[object Object],[object Object],[object Object]
Six-part Asthma Management Program:   Summary  (continued) ,[object Object],[object Object]
Thank you !!

Mais conteúdo relacionado

Mais procurados

Asthma in the acute care setting
Asthma in the acute care settingAsthma in the acute care setting
Asthma in the acute care settingDr.Mahmoud Abbas
 
GINA ASTHMA GUIDELINES UPDATE 2018
GINA ASTHMA GUIDELINES UPDATE 2018GINA ASTHMA GUIDELINES UPDATE 2018
GINA ASTHMA GUIDELINES UPDATE 2018Mrinmoy ROY
 
1 whats-new-in-gina-2018 v1.2
1 whats-new-in-gina-2018 v1.21 whats-new-in-gina-2018 v1.2
1 whats-new-in-gina-2018 v1.2Hiba Ashibany
 
ACOS Working Group Meeting
ACOS Working Group MeetingACOS Working Group Meeting
ACOS Working Group MeetingZoe Mitchell
 
GINA 2020 Guidelines for Asthma
GINA 2020 Guidelines for AsthmaGINA 2020 Guidelines for Asthma
GINA 2020 Guidelines for Asthmamahimakura1
 
GOLD (COPD) & GINA (Asthma) guidelines: 2018 update
GOLD (COPD) & GINA (Asthma) guidelines: 2018 updateGOLD (COPD) & GINA (Asthma) guidelines: 2018 update
GOLD (COPD) & GINA (Asthma) guidelines: 2018 updatePranav Sopory
 
Status asthmaticus
Status asthmaticusStatus asthmaticus
Status asthmaticusReynel Dan
 
Therapies For Severe Asthma
Therapies For Severe AsthmaTherapies For Severe Asthma
Therapies For Severe AsthmaDang Thanh Tuan
 
HỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOS
HỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOSHỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOS
HỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOSSoM
 
Gold slide set_2017
Gold slide set_2017Gold slide set_2017
Gold slide set_2017Safaa Abbas
 
Bronchial asthma review
Bronchial asthma review Bronchial asthma review
Bronchial asthma review Azad Haleem
 
Updates on Asthma and COPD
Updates on Asthma and COPD Updates on Asthma and COPD
Updates on Asthma and COPD Chew Keng Sheng
 
Format 2016: tachypnoea in a well baby: what to do next?
Format 2016: tachypnoea in a well baby: what to do next?Format 2016: tachypnoea in a well baby: what to do next?
Format 2016: tachypnoea in a well baby: what to do next?Envicon Medical Srl
 

Mais procurados (20)

Asthma in the acute care setting
Asthma in the acute care settingAsthma in the acute care setting
Asthma in the acute care setting
 
Asthma a/c to pharmacy
Asthma a/c to pharmacyAsthma a/c to pharmacy
Asthma a/c to pharmacy
 
COPD Asthma Workshop
COPD Asthma Workshop COPD Asthma Workshop
COPD Asthma Workshop
 
Copd 2006
Copd 2006Copd 2006
Copd 2006
 
GINA ASTHMA GUIDELINES UPDATE 2018
GINA ASTHMA GUIDELINES UPDATE 2018GINA ASTHMA GUIDELINES UPDATE 2018
GINA ASTHMA GUIDELINES UPDATE 2018
 
Childhood asthma
Childhood asthmaChildhood asthma
Childhood asthma
 
1 whats-new-in-gina-2018 v1.2
1 whats-new-in-gina-2018 v1.21 whats-new-in-gina-2018 v1.2
1 whats-new-in-gina-2018 v1.2
 
ACOS Working Group Meeting
ACOS Working Group MeetingACOS Working Group Meeting
ACOS Working Group Meeting
 
GINA 2020 Guidelines for Asthma
GINA 2020 Guidelines for AsthmaGINA 2020 Guidelines for Asthma
GINA 2020 Guidelines for Asthma
 
GOLD (COPD) & GINA (Asthma) guidelines: 2018 update
GOLD (COPD) & GINA (Asthma) guidelines: 2018 updateGOLD (COPD) & GINA (Asthma) guidelines: 2018 update
GOLD (COPD) & GINA (Asthma) guidelines: 2018 update
 
Refractory Asthma
Refractory AsthmaRefractory Asthma
Refractory Asthma
 
Status asthmaticus
Status asthmaticusStatus asthmaticus
Status asthmaticus
 
Therapies For Severe Asthma
Therapies For Severe AsthmaTherapies For Severe Asthma
Therapies For Severe Asthma
 
HỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOS
HỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOSHỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOS
HỘI CHỨNG CHỒNG LẤP HEN PHẾ QUẢN VÀ COPD _ ACOS
 
Gold slide set_2017
Gold slide set_2017Gold slide set_2017
Gold slide set_2017
 
Asthma
AsthmaAsthma
Asthma
 
Bronchial asthma review
Bronchial asthma review Bronchial asthma review
Bronchial asthma review
 
Updates on Asthma and COPD
Updates on Asthma and COPD Updates on Asthma and COPD
Updates on Asthma and COPD
 
Aspirin exacerbated respiratory disease
Aspirin exacerbated respiratory diseaseAspirin exacerbated respiratory disease
Aspirin exacerbated respiratory disease
 
Format 2016: tachypnoea in a well baby: what to do next?
Format 2016: tachypnoea in a well baby: what to do next?Format 2016: tachypnoea in a well baby: what to do next?
Format 2016: tachypnoea in a well baby: what to do next?
 

Destaque

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文internalmed
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13internalmed
 
4 pleural effusions
4 pleural effusions4 pleural effusions
4 pleural effusionsinternalmed
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhouinternalmed
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathyinternalmed
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeinternalmed
 
4 bronchiectasis
4 bronchiectasis4 bronchiectasis
4 bronchiectasisinternalmed
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosisinternalmed
 
23 renal disease
23 renal disease23 renal disease
23 renal diseaseinternalmed
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitisinternalmed
 
Uti english ppts
Uti english pptsUti english ppts
Uti english pptsinternalmed
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial diseaseinternalmed
 

Destaque (20)

Anemia
AnemiaAnemia
Anemia
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
15 ie
15 ie15 ie
15 ie
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
 
4 pleural effusions
4 pleural effusions4 pleural effusions
4 pleural effusions
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
 
1 introduction
1 introduction1 introduction
1 introduction
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
 
4 bronchiectasis
4 bronchiectasis4 bronchiectasis
4 bronchiectasis
 
6 lungcancer
6 lungcancer6 lungcancer
6 lungcancer
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
7 cor pulmonale
7 cor pulmonale7 cor pulmonale
7 cor pulmonale
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
 
Uti english ppts
Uti english pptsUti english ppts
Uti english ppts
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
 

Semelhante a 9 asthma (20)

8
88
8
 
Pharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospitalPharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospital
 
Asthma
AsthmaAsthma
Asthma
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
 
Child asthma
Child asthmaChild asthma
Child asthma
 
Obstructive lung disease
Obstructive lung diseaseObstructive lung disease
Obstructive lung disease
 
Childhood asthma.pptx
Childhood asthma.pptxChildhood asthma.pptx
Childhood asthma.pptx
 
Chronic obstructive pulmonary disease ppt
Chronic obstructive pulmonary disease   pptChronic obstructive pulmonary disease   ppt
Chronic obstructive pulmonary disease ppt
 
Shortness of breath
Shortness of breathShortness of breath
Shortness of breath
 
Asthma
AsthmaAsthma
Asthma
 
Gina - global initiative against asthma
Gina - global initiative against asthmaGina - global initiative against asthma
Gina - global initiative against asthma
 
jodhpur presentation [Autosaved].pptx12 final copy1-1.pptx
jodhpur presentation [Autosaved].pptx12 final copy1-1.pptxjodhpur presentation [Autosaved].pptx12 final copy1-1.pptx
jodhpur presentation [Autosaved].pptx12 final copy1-1.pptx
 
Bronchial asthma madi sasi 2019
Bronchial  asthma madi sasi  2019Bronchial  asthma madi sasi  2019
Bronchial asthma madi sasi 2019
 
Global Initiative For Asthma Guidelines 2008
Global Initiative For Asthma Guidelines 2008Global Initiative For Asthma Guidelines 2008
Global Initiative For Asthma Guidelines 2008
 
Bronchial asthama and pregnancys
Bronchial asthama and pregnancysBronchial asthama and pregnancys
Bronchial asthama and pregnancys
 
Asthma Talk For Obgyn
Asthma Talk For ObgynAsthma Talk For Obgyn
Asthma Talk For Obgyn
 
Asthma attack reatment abreviated
Asthma  attack reatment abreviatedAsthma  attack reatment abreviated
Asthma attack reatment abreviated
 
Asthma
Asthma  Asthma
Asthma
 
Asthma
AsthmaAsthma
Asthma
 
Asthma
AsthmaAsthma
Asthma
 

Mais de internalmed

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular diseaseinternalmed
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitisinternalmed
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gaointernalmed
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
13 respiratory failure
13 respiratory failure13 respiratory failure
13 respiratory failureinternalmed
 
11 heart failure
11 heart failure11 heart failure
11 heart failureinternalmed
 

Mais de internalmed (14)

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
 
18 peptic ulcer
18 peptic ulcer18 peptic ulcer
18 peptic ulcer
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Anemia
AnemiaAnemia
Anemia
 
13 respiratory failure
13 respiratory failure13 respiratory failure
13 respiratory failure
 
11 heart failure
11 heart failure11 heart failure
11 heart failure
 
10 hypertension
10 hypertension10 hypertension
10 hypertension
 

Último

Using Grammatical Signals Suitable to Patterns of Idea Development
Using Grammatical Signals Suitable to Patterns of Idea DevelopmentUsing Grammatical Signals Suitable to Patterns of Idea Development
Using Grammatical Signals Suitable to Patterns of Idea Developmentchesterberbo7
 
Oppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and FilmOppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and FilmStan Meyer
 
How to Fix XML SyntaxError in Odoo the 17
How to Fix XML SyntaxError in Odoo the 17How to Fix XML SyntaxError in Odoo the 17
How to Fix XML SyntaxError in Odoo the 17Celine George
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management SystemChristalin Nelson
 
4.9.24 School Desegregation in Boston.pptx
4.9.24 School Desegregation in Boston.pptx4.9.24 School Desegregation in Boston.pptx
4.9.24 School Desegregation in Boston.pptxmary850239
 
Textual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHSTextual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHSMae Pangan
 
ARTERIAL BLOOD GAS ANALYSIS........pptx
ARTERIAL BLOOD  GAS ANALYSIS........pptxARTERIAL BLOOD  GAS ANALYSIS........pptx
ARTERIAL BLOOD GAS ANALYSIS........pptxAneriPatwari
 
Tree View Decoration Attribute in the Odoo 17
Tree View Decoration Attribute in the Odoo 17Tree View Decoration Attribute in the Odoo 17
Tree View Decoration Attribute in the Odoo 17Celine George
 
BIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptx
BIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptxBIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptx
BIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptxSayali Powar
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4JOYLYNSAMANIEGO
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfPatidar M
 
Scientific Writing :Research Discourse
Scientific  Writing :Research  DiscourseScientific  Writing :Research  Discourse
Scientific Writing :Research DiscourseAnita GoswamiGiri
 
Grade Three -ELLNA-REVIEWER-ENGLISH.pptx
Grade Three -ELLNA-REVIEWER-ENGLISH.pptxGrade Three -ELLNA-REVIEWER-ENGLISH.pptx
Grade Three -ELLNA-REVIEWER-ENGLISH.pptxkarenfajardo43
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
Mythology Quiz-4th April 2024, Quiz Club NITW
Mythology Quiz-4th April 2024, Quiz Club NITWMythology Quiz-4th April 2024, Quiz Club NITW
Mythology Quiz-4th April 2024, Quiz Club NITWQuiz Club NITW
 
Decoding the Tweet _ Practical Criticism in the Age of Hashtag.pptx
Decoding the Tweet _ Practical Criticism in the Age of Hashtag.pptxDecoding the Tweet _ Practical Criticism in the Age of Hashtag.pptx
Decoding the Tweet _ Practical Criticism in the Age of Hashtag.pptxDhatriParmar
 
Sulphonamides, mechanisms and their uses
Sulphonamides, mechanisms and their usesSulphonamides, mechanisms and their uses
Sulphonamides, mechanisms and their usesVijayaLaxmi84
 

Último (20)

Faculty Profile prashantha K EEE dept Sri Sairam college of Engineering
Faculty Profile prashantha K EEE dept Sri Sairam college of EngineeringFaculty Profile prashantha K EEE dept Sri Sairam college of Engineering
Faculty Profile prashantha K EEE dept Sri Sairam college of Engineering
 
Using Grammatical Signals Suitable to Patterns of Idea Development
Using Grammatical Signals Suitable to Patterns of Idea DevelopmentUsing Grammatical Signals Suitable to Patterns of Idea Development
Using Grammatical Signals Suitable to Patterns of Idea Development
 
Oppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and FilmOppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and Film
 
How to Fix XML SyntaxError in Odoo the 17
How to Fix XML SyntaxError in Odoo the 17How to Fix XML SyntaxError in Odoo the 17
How to Fix XML SyntaxError in Odoo the 17
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management System
 
4.9.24 School Desegregation in Boston.pptx
4.9.24 School Desegregation in Boston.pptx4.9.24 School Desegregation in Boston.pptx
4.9.24 School Desegregation in Boston.pptx
 
Textual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHSTextual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHS
 
ARTERIAL BLOOD GAS ANALYSIS........pptx
ARTERIAL BLOOD  GAS ANALYSIS........pptxARTERIAL BLOOD  GAS ANALYSIS........pptx
ARTERIAL BLOOD GAS ANALYSIS........pptx
 
Tree View Decoration Attribute in the Odoo 17
Tree View Decoration Attribute in the Odoo 17Tree View Decoration Attribute in the Odoo 17
Tree View Decoration Attribute in the Odoo 17
 
BIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptx
BIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptxBIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptx
BIOCHEMISTRY-CARBOHYDRATE METABOLISM CHAPTER 2.pptx
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdf
 
Scientific Writing :Research Discourse
Scientific  Writing :Research  DiscourseScientific  Writing :Research  Discourse
Scientific Writing :Research Discourse
 
Grade Three -ELLNA-REVIEWER-ENGLISH.pptx
Grade Three -ELLNA-REVIEWER-ENGLISH.pptxGrade Three -ELLNA-REVIEWER-ENGLISH.pptx
Grade Three -ELLNA-REVIEWER-ENGLISH.pptx
 
Mattingly "AI & Prompt Design: Large Language Models"
Mattingly "AI & Prompt Design: Large Language Models"Mattingly "AI & Prompt Design: Large Language Models"
Mattingly "AI & Prompt Design: Large Language Models"
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
Mythology Quiz-4th April 2024, Quiz Club NITW
Mythology Quiz-4th April 2024, Quiz Club NITWMythology Quiz-4th April 2024, Quiz Club NITW
Mythology Quiz-4th April 2024, Quiz Club NITW
 
prashanth updated resume 2024 for Teaching Profession
prashanth updated resume 2024 for Teaching Professionprashanth updated resume 2024 for Teaching Profession
prashanth updated resume 2024 for Teaching Profession
 
Decoding the Tweet _ Practical Criticism in the Age of Hashtag.pptx
Decoding the Tweet _ Practical Criticism in the Age of Hashtag.pptxDecoding the Tweet _ Practical Criticism in the Age of Hashtag.pptx
Decoding the Tweet _ Practical Criticism in the Age of Hashtag.pptx
 
Sulphonamides, mechanisms and their uses
Sulphonamides, mechanisms and their usesSulphonamides, mechanisms and their uses
Sulphonamides, mechanisms and their uses
 

9 asthma

  • 1. Asthma Zhiwen Zhu Pulmonary & Critical Care Medicine 1st Affiliated Hospital of Sun Yat-Sen University
  • 2. Beethoven Ludwig van He was a patient with asthma, and died in 1827.
  • 3. Teresa Deng She was also a patient with asthma, and died in 1995.
  • 5. G IN A lobal itiative for sthma
  • 6.
  • 7.
  • 8.
  • 9. Worldwide Variation in Prevalence of Asthma Symptoms International Study of Asthma and Allergies in Children (ISAAC) Lancet 1998;351:1225
  • 10. Increasing Prevalence of Asthma in Children/Adolescents 0 5 10 15 20 25 30 35 1992 1982 1989 1975 1992 1982 1994 1989 1992 1982 1992 1982 1991 1979 1989 1966 Finland (Haahtela et al ) Sweden (Aberg et al ) Japan (Nakagomi et al ) Scotland (Rona et al ) UK (Omran et al ) USA (NHIS) New Zealand (Shaw et al ) Australia (Peat et al ) { Prevalence (%) { { { { { { {
  • 11. 70 60 50 40 30 20 85 86 87 88 89 90 91 92 93 94 Rate/1,000 Persons Year <18 18-44 45-64 65+ Total (All Ages) Age (years) Trends in Prevalence of Asthma By Age, U.S., 1985-1996 95 96 80
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.  
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Typical Spirometric (FEV 1 ) Tracings 1 Time (sec) 2 3 4 5 FEV 1 Volume Normal Subject Asthmatic (After Bronchodilator) Asthmatic (Before Bronchodilator) Note: Each FEV 1 curve represents the highest of three repeat measurements
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29. Pointers that differentiate asthma from COPD   COPD Asthma History     Smoker or ex-smoker Nearly all Possibly Symptoms under age 45 Uncommon Often Chronic productive cough Common Uncommon Breathlessness Persistent and progressive Variable Winter bronchitis Common Uncommon Investigations     Serial PEF Obstructive picture May be normal Day to day and diurnal variation Reversibility testing Minimal variation Usually<15% or 200ml change Usually>15% or 200ml change
  • 30.
  • 31. Classification of Severity of chronic stable asthma CLASSIFY SEVERITY Clinical Features Before Treatment Symptoms Nocturnal Symptoms FEV 1 or PEF STEP 4 Severe Persistent STEP 3 Moderate Persistent STEP 2 Mild Persistent STEP 1 Intermittent Continuous Limited physical activity Daily Attacks affect activity > 1 time a week but < 1 time a day < 1 time a week Asymptomatic and normal PEF between attacks Frequent > 1 time a week > 2 times a month  2 times a month  60% predicted Variability > 30% 60 - 80% predicted Variability > 30%  80% predicted Variability 20 - 30%  80% predicted Variability < 20% The presence of one feature of severity is sufficient to place patient in that category.
  • 33. Classification of severity of asthma exacerbation <91 >45 <60 Relative bradycardia Consciousness Impending respiratory failure <91 >45 <60 <60% >120 >30 At rest Severe 91~95 <45 60~80 60-80% 100~120 ↑ With talking Moderate >95 <45 normal >80% <100 ↑ With activity Mild SaO2 PaCO2 PaO2 PEF/FEV1 HR RR breathlessness
  • 34. Six-Part Asthma Management Program 1. Educate patients to develop a partnership in asthma management 2. Assess and monitor asthma severity with symptom reports and measures of lung function as much as possible 3. Avoid exposure to risk factors 4. Establish medication plans for chronic management in children and adults 5. Establish individual plans for managing exacerbations 6. Provide regular follow-up care
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56. Emergency Department Management Acute Asthma Respiratory Failure Admit to ICU Good Response Observe for at least 1 hour If Stable, Discharge to Home Initial Assessment History, Physical Examination, PEF or FEV 1 Initial Therapy Bronchodilators; O 2 if needed Incomplete/Poor Response Add Systemic Glucocorticosteroids Good Response Discharge Poor Response Admit to Hospital
  • 57.
  • 58.
  • 59.

Notas do Editor

  1. © GlaxoSmithKline 2002
  2. © GlaxoSmithKline 2002
  3. © GlaxoSmithKline 2002